formulation

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis in

Malaysian Genomics to Collaborate on Cannabinoid R&D

Group joins MAHSA University and Kensana Health to develop phytopharmaceutical and biotechnology products for commercialisation PETALING JAYA, Malaysia, Feb 24, 2023 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, today announced that the Group has entered into a strategic collaboration with Kensana Health Canada and MAHSA University for the research and development (R&D) of phytopharmaceutical and biotechnology products that can lead to commercialisation. [caption id="attachment_1975874" align="alignnone" width="350"] Dato' Alvin Joseph Nesakumar, Executive Director of Malaysian Genomics[/caption] Kensana Health Canada is a biotechnology specialist